ConductScience.org, home

Paper7941328

Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.

Spear GT and 4 others. Virology, 1994. Cited by 46 papers, by iCite.

Cite this record

ConductScience Library. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Papers, record 7941328. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7941328

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
PubMed
Journal
Virology
PubMed
Year
1994
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
1.04
iCite
Revised in PubMed
2007-11-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Spear GTG T
2Takefman DMD M
3Sharpe SS
4Ghassemi MM
5Zolla-Pazner SS

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Acquired Immunodeficiency SyndromeMajor topic
Complement ActivationMajor topic
HIV AntibodiesMajor topic
HIV-1Major topic
Amino Acid Sequence
Complement C3
Humans
Molecular Sequence Data
Neutralization Tests

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
AI29661NIAID NIH HHSUnited StatesR01AI029661PubMed and NIHNIH RePORTER
AI31812NIAID NIH HHSUnited StatesR01AI031812PubMed and NIHNIH RePORTER
AI32424NIAID NIH HHSUnited StatesR01AI032424PubMed and NIHNIH RePORTER
R29AI031812NIHNIH RePORTER

Download CSV of grants

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
31833228Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.EMBO Rep2020https://conductscience.org/library/papers/31833228PubMed
29237828Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.J Virol2018https://conductscience.org/library/papers/29237828PubMed
27657055Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.Int J Mol Sci2016https://conductscience.org/library/papers/27657055PubMed
26842476
Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
J Virol2016https://conductscience.org/library/papers/26842476PubMed
26109728Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.J Virol2015https://conductscience.org/library/papers/26109728PubMed
25122783Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.J Virol2014https://conductscience.org/library/papers/25122783PubMed
24314667
Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.
Virology2014https://conductscience.org/library/papers/24314667PubMed
22012269Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Arch Virol2012https://conductscience.org/library/papers/22012269PubMed
15039757Identifying epitopes of HIV-1 that induce protective antibodies.Nat Rev Immunol2004https://conductscience.org/library/papers/15039757PubMed
12719582Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.J Virol2003https://conductscience.org/library/papers/12719582PubMed
12186887Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.J Virol2002https://conductscience.org/library/papers/12186887PubMed
11752155
A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
J Virol2002https://conductscience.org/library/papers/11752155PubMed
10364275
Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
J Virol1999https://conductscience.org/library/papers/10364275PubMed
10233749B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.Immunology1999https://conductscience.org/library/papers/10233749PubMed
9811721Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.J Virol1998https://conductscience.org/library/papers/9811721PubMed
9765439Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.J Virol1998https://conductscience.org/library/papers/9765439PubMed
9371578The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.J Virol1997https://conductscience.org/library/papers/9371578PubMed
7666524Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.J Virol1995https://conductscience.org/library/papers/7666524PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
C3718PubTator's text mininghttps://conductscience.org/library/genes/718NCBI Gene
ENPEP2028PubTator's text mininghttps://conductscience.org/library/genes/2028NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7941328

GET https://conductscience.org/api/papers/v1/7941328/authors